NeuroSense Therapeutics Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRSN research report →
Companywww.neurosense-tx.com
NeuroSense Therapeutics Ltd. , a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis.
- CEO
- Alon Ben-Noon
- IPO
- 2021
- Employees
- 17
- HQ
- Herzliya, IL
Price Chart
Valuation
- Market Cap
- $19.98M
- P/E
- -3.16
- P/S
- 0.00
- P/B
- -13.19
- EV/EBITDA
- -3.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 173600.00%
- ROIC
- 464.96%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-11,125,000 · -8.96%
- EPS
- $-0.44 · 20.00%
- Op Income
- $-11,085,000
- FCF YoY
- 24.26%
Performance & Tape
- 52W High
- $2.60
- 52W Low
- $0.63
- 50D MA
- $0.79
- 200D MA
- $0.99
- Beta
- 1.58
- Avg Volume
- 149.84K
Get TickerSpark's AI analysis on NRSN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 26, 26 | Eisenberg Or | other | 200,000 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Jul 1, 21 | Eisenberg Or | other | 21,000 |
| Aug 15, 24 | Eisenberg Or | other | 66,666 |
| Mar 18, 26 | Mandil-Levin Revital | other | 0 |
| Mar 18, 26 | Mandil-Levin Revital | other | 0 |
| Mar 18, 26 | Mandil-Levin Revital | other | 0 |
| Mar 10, 23 | Mandil-Levin Revital | other | 72,000 |
Our NRSN Coverage
We haven't published any research on NRSN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NRSN Report →